Avéma Pharma Solutions is pleased to be attending CPhI in Philadelphia (April 25-27, Pennsylvania Convention Center) at Booth #1024. We look forward to seeing our customers and prospects in person and sharing the exciting new developments at Avéma.
To support our expanding business in the development and manufacture of oral liquid and solid-dose prescription and OTC drugs, Avéma Pharma Solutions and its parent company, PL Developments, have acquired a new 135,000-square-foot facility in Miami. The new site will triple the size of the R&D and analytical labs, and will allow future manufacturing growth and warehousing needs for the company’s Florida operations — serving both its CDMO customer base and its private-label offerings. This site is the company’s 10th location in the U.S.
As a fully-integrated CDMO, Avéma offers its contract customers services that range from R&D development to pilot-scale manufacturing to commercial manufacturing and bottling. Avéma’s commitment to design of experiment (DoE) techniques can help reduce FDA review time for new product submissions. This streamlined approach helps companies accelerate R&D and efficiently transfer to commercial production quickly and cost-effectively, cutting weeks out of traditional timelines.
Avéma Pharma Solutions has more than 33 years of Rx formulation development experience and offers a wide range of product capabilities, including small-volume pilot-scale production capabilities, high-potency compounds and small molecule drug development, as well as designing drug delivery systems, such as:
As a wholly-owned subsidiary of PL Developments, one of the largest private label companies in the U.S, Avéma leverages the resources and expertise of both companies to help customers bring products to market quickly, efficiently, and cost-effectively. The advantages of working with Avéma and PLD include:
New Gummy Manufacturing Capabilities in Copiague, NY
In addition to its investment in Miami, PL Developments and Avéma have purchased a CFR 2111 and CFR 111- compliant facility in Copiague, NY which manufactures gums and gummies. With this investment, Avéma and PLD are looking to leverage their extensive experience in solid dosage formats to include novel delivery systems like gummies. To that end, Avéma has setup a world class benchtop lab in our Miami R&D center to help facilitate rapid gummy development and hired Mitchell Slade, who has extensive experience in gummy manufacturing at Nature’s Bounty, as President of Avéma Gummy Solutions, to drive the effort on development and formulations.
The Copiague facility currently has four manufacturing lines with the capability of producing ~1.2bn gummies annually.
Avéma Pharma Solutions is a division of PL Developments — a leading manufacturer, packager, and distributor of over-the-counter (OTC) pharmaceutical products and consumer health care goods. Avéma Pharma Solutions offers complete, turnkey product development and manufacturing solutions at Miami facility, including R&D, product development, validation, testing, demonstration batches, small-scale manufacturing, and transfer to commercial levels.